换一批Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
第一作者：
Keichiro,Mihara
第一单位：
Department of Haematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan. kmmihara@hiroshima-u.ac.jp
作者：
医学主题词
动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗原, CD19(Antigens, CD19);抗原, 肿瘤(Antigens, Neoplasm);抗肿瘤药(Antineoplastic Agents);细胞死亡(Cell Death);综合疗法(Combined Modality Therapy);细胞毒性, 免疫(Cytotoxicity, Immunologic);女(雌)性(Female);遗传载体(Genetic Vectors);人类(Humans);免疫疗法(Immunotherapy);淋巴瘤, B细胞(Lymphoma, B-Cell);膜糖蛋白类(Membrane Glycoproteins);小鼠(Mice);小鼠, 近交NOD(Mice, Inbred NOD);小鼠, SCID(Mice, SCID);受体, 抗原(Receptors, Antigen);逆转录病毒科(Retroviridae);T淋巴细胞(T-Lymphocytes);肿瘤细胞, 培养的(Tumor Cells, Cultured);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.1111/j.1365-2141.2010.08297.x
PMID
20678160
发布时间
2017-11-16
- 浏览27
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
